PR Newswire

The newsfeed available here is provided by our content partner PR Newswire. This is one of the most important and widest-reaching press services, providing news, press releases and multimedia content to the media, journalists and the public.
The NewsWire Hub ("X-Billboard") currently comprises four of the most important international news sources and is supplemented by a stock market information service. The individual newswire services complement each other and provide a complementary range of information, more than three quarters of the official news sources on which editors worldwide base their stock market reporting. Your advantage: You will find everything here in one overview. You can navigate to the individual sections using the control elements. In the terminal view, you can carry out individual searches at company level.
presented by
N
More Tools & Gadgets
F&G: 35
5.523,04 S&P · 23,48 Vola-Index · 95.004,71 BTC · 1,13637 EURUSD
System-State: Number of processed items 86.236 Notifications successully processed since Inception
EXCHANGE NEWSBOARD
                              
NEWSWIRE INFOBOARD
                              
PR Newswire is an important news source that can be accessed via the X-Billboard. It is part of the Newswire Hub, which bundles important international news sources for stock market participants in one central location. If you want to get a quick overview, you can easily scroll through the headlines. If you want to look at the news in more detail, you can use the detailed views of the info cards to directly access the respective news item and other analysis tools.
NEWS
EXPLORER
GB0009252882
State: 26.04.2025 | 7AM
Do you already know our new terminal view? Click here.
FIGI: BBG000H7K468
GSK
GlaxoSmithKline plc
GICS: - · Sector: Drugs · Sub-Sector: -
NAME
GlaxoSmithKline plc
ISIN
GB0009252882
TICKER
GSK
MIC
XLON
REUTERS
GSK.L
BLOOMBERG
GSK LN
Wed, 26.03.2025       GSK
GB0009252882

MONTRÉAL, March 25, 2025 /CNW/ - ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. and Shionogi as shareholders, is pleased to announce that APRETUDE (cabotegravir tablets and extended release injectable suspension) is now covered under the federal Non-Insured Health Benefits (NIHB) Program for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in at risk individuals who are HIV-1 negative.1

Read More
GSK
Technical Analysis Termsheet Terminal
Permalink
Thu, 13.02.2025       GSK
GB0009252882

MONTRÉAL, Feb. 13, 2025 /CNW/ - ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. and Shionogi as shareholders, is pleased to announce it has successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for APRETUDE (cabotegravir tablets and extended release injectable suspension) for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in at-risk individuals who are HIV-1 negative.1

Read More
GSK
Technical Analysis Termsheet Terminal
Permalink
Mon, 16.09.2024       GSK
GB0009252882

Brooke Shields convenes other celebrities, influencers and patient advocates over 50 to discuss the power of aging and how to protect their healthShields directs a short film, encouraging adults 50 years of age and older to talk to their doctor or pharmacist about their risk for shingles — a disease that affects about 1 million people annually in the US — and about vaccinationThe partnership is part of GSK's national THRIVE@50+ campaign

PHILADELPHIA, Sept. 16, 2024 /PRNewswire/ -- GSK plc (LSE/NYSE: GSK) is partnering with Brooke Shields, as part of its THRIVE@50+ campaign, to encourage people 50 and older to embrace and protect the power they've found in aging by asking their doctor or pharmacist about their risk for shingles and about vaccination.

Read More
GSK
Technical Analysis Termsheet Terminal
Permalink
Wed, 31.07.2024       GSK
GB0009252882

Largest head-to-head randomized clinical trial between DTG/3TC and BIC/FTC/TAF, conducted by SEIMC-GeSIDA Foundation (FSG) showed DTG/3TC demonstrated non-inferior efficacy compared to BIC/FTC/TAF as a switch regimen for virologically-suppressed adults living with HIV over 48 weeks of therapy.DTG/3TC-treated individuals had significantly less weight gain compared to those randomized to BIC/FTC/TAF. In 2022, the Canadian HIV incidence rate grew by 15% in comparison to 2020, a total of 1,848 new cases. 1According to the latest surveyed data, there is an estimated 65,270 Canadians living with HIV. 1
Read More
GSK
Technical Analysis Termsheet Terminal
Permalink

The information provided here is not subject to any editorial processing. It is prepared fully automatically and enriched with additional information and further research options. The aim of the content is to provide information seekers with the relevant information quickly and easily. A link back to the information provider and owner ensures that the data prepared here can be compared with the source information if required. The newsboard does not show information in real time. Please contact the exchange operator for this information if required. There is no claim to completeness. High availability cannot be guaranteed. If you notice any errors in the functionality, please let us know using the "Report a Bug" form below.

RAW DATA PROCESSING means that raw data is processed without changing the content. The data is supplemented to improve the interpretation of the information in terms of usability.

Note: The newswire cross-link panel at the top allows you to quickly and easily access additional sources of information. In the terminal view, the news is filtered at company level and enables targeted searches.

On behalf of the trading community, we would like to thank the operators of the trading venues for providing information services.